Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
Heres what makes it appetite-neutral: Mechanism: Activates lipolysis via beta-3 adrenergic receptors in fat tissue Appetite Impact: No effect on hunger, satiety, or food intake patterns Cortisol: Does not elevate cortisol levels (unlike full growth hormone) Administration: Subcutaneous injection, typically daily Typical Dosing: 250-500 mcg daily before breakfast Metabolic Effects: Increases fat oxidation without affecting insulin or glucose Best For: Individuals seeking fat loss while maintaining normal eating patterns Key Difference: Works directly on fat tissue, not through appetite regulation The following guide provides complete details on AOD-9604s appetite-neutral fat loss mechanism, from cellular pathways to practical implementation protocols
Frontier Peptide Labs 5-Amino-1MQ Vial is intended exclusively for laboratory research and development purposes
Not automatically
Common research characteristics: Compound type: Synthetic small molecule (research compound) Primary targets studied: ERR / ERR / ERR (non-selective agonist profile) Research focus: Nuclear receptor signaling, transcriptional regulation, mitochondrial-related gene programs Use setting: Controlled in vitro assays and non-clinical research models SLU-PP-332 10 vial kit peptide Storage & Handling All peptides are supplied as sterile, lyophilized powder and are stable when handled correctly
Clinical trials evaluated AOD-9604 for durations ranging from single doses to 24 weeks of continuous daily administration
US$ 22.58
US$ 26.52
US$ 29.50
